Year Established :
1998
Total Assets(USD) :
45,000,000 To 49,999,999
Total Number of Staff :
50 to 59
Other Competitive Advantages :
customized product
fast reply
Business Type :
Trading Company,Service Provider
R&D Capacity :
Other
Annual Turnover(USD) :
45,000,000 To 49,999,999
Main Sales Markets :
North America,Central/South America,Western Europe,Eastern Europe,Asia,Middle East
Main Product Categorise :
Active Pharmaceutical Ingredients,Intermediates,Fine Chemicals
Product Range :
API & Intermediates of the following APIs:
LCZ696
Losartan Potassium
Telmisartan
Rosuvastatin Calcium
Afatinib
Abiraterone Acetate
Dasatinib
Ibrutinib
Palbociclib
Rolapitant
Sunitinib Malate
Venetoclax
Atazanavir
Cobicistat
Dolutegravir
Ledipasvir
Oseltamivir
Raltegravir Potassium
Sofosbuvir
Tenofovir Disoproxil Fumarate
Velpatasvir
Ticagrelor
Edoxaban Tosylate
Clopidogrel Hydrogen Sulfate
Isavuconazonium Sulfate
Posaconazole
Apremilast
Aripiprazole
Eluxadoline Dihydrochloride
Glatiramer Acetate
Lesinurad
Lomitapide Mesylate
Mirabegron
Obeticholic Acid
Perampanel
Pirfenidone
Teneligliptin Hydrobromide
Tofacitinib Citrate
Vildagliptin
Sitagliptin phosphate
Brivaracetam
Sarpogrelate
Six years of qualification
Audited Supplier
Pharma Sources Insight January 2025
